# ProQR Therapeutics (PRQR) — Analyst Forecast

PRQR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/prqr/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 10 | 0 | 0 | 10 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $3.00 | $6.33 | $8.00 | 3 |

Last price $1.45 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 1, 2026 | HC Wainwright & Co. | Maintained | Buy | $8.00 |
| Oct 1, 2026 | Chardan Capital | Maintained | Buy | $3.00 |
| Aug 20, 2026 | B of A Securities | Initiated Coverage | Buy | $8.00 |
| Jun 29, 2026 | Evercore ISI Group | Maintained | Outperform | $6.00 |
| Jun 26, 2026 | Chardan Capital | Maintained | Buy | $3.00 |
| Jun 26, 2026 | Jones Trading | Maintained | Buy | $10.00 |
| Apr 9, 2026 | Chardan Capital | Maintained | Buy | $4.00 |
| Nov 4, 2025 | Chardan Capital | Maintained | Buy | $4.00 |
| Aug 8, 2025 | Chardan Capital | Maintained | Buy | $4.00 |
| Jun 27, 2025 | Cantor Fitzgerald | Maintained | Overweight | $8.00 |
| Jun 27, 2025 | JMP Securities | Maintained | Market Outperform | $8.00 |
| May 13, 2025 | Oppenheimer | Maintained | Outperform | $9.00 |
| Apr 29, 2025 | Evercore ISI Group | Initiated Coverage | Outperform | $5.00 |
| Mar 14, 2025 | Chardan Capital | Maintained | Buy | $4.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Maintained | Buy | $12.00 |
| Feb 12, 2025 | Jones Trading | Initiated Coverage | Buy | $11.00 |
| Dec 12, 2024 | HC Wainwright & Co. | Maintained | Buy | $10.00 |
| Dec 12, 2024 | Chardan Capital | Maintained | Buy | $4.00 |
| Dec 12, 2024 | JMP Securities | Maintained | Market Outperform | $8.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Maintained | Buy | $10.00 |

## Frequently Asked Questions

### What is the price target for PRQR stock?

The average 12-month analyst price target for ProQR Therapeutics (PRQR) is $6.33, with a high estimate of $8.00 and a low of $3.00, across 3 analysts.

### Is PRQR a buy, sell, or hold?

Analysts covering ProQR Therapeutics currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for PRQR?

The average price target of $6.33 implies 336.78% upside from the last price of $1.45.

### What is the latest analyst rating on PRQR?

On Oct 1, 2026, HC Wainwright & Co. maintained ProQR Therapeutics at Buy with a price target of $8.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).